Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

References

• Pettitt D, Arshad Z, Smith J, Stanic T, Holländer G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther J Am Soc Gene Ther. 2018;26:342–53. doi:10.1016/j.ymthe.2017.10.019.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–75. doi:10.1016/j.pharmthera.2017.08.005.
   PubMed Web of Science ®Google Scholar
• Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985;316:354–56. doi:10.1038/316354a0.
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314:628–31. doi:10.1038/314628a0.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–77. doi:10.1126/science.1158545.
   PubMed Web of Science ®Google Scholar
• Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478–83. doi:10.1038/bjc.1998.518.
   PubMed Web of Science ®Google Scholar
• Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, et al. Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17:776–85. doi:10.1158/1535-7163.MCT-17-0657.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall’Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep [Internet]. 2017;7. [accessed 2018 Dec 28]. http://www.nature.com/articles/srep40098.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–57. doi:10.1182/blood-2013-02-485623.
   PubMed Web of Science ®Google Scholar
• Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, Thorpe SJ, Wadhwa M, Thorpe R, Stebbings R. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol. 2013;76:299–315. doi:10.1111/bcp.12040.
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018;131:30–38.
   PubMed Web of Science ®Google Scholar
• Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Müller S, Valitutti S. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S A. 2003;100:14145–50. doi:10.1073/pnas.2334336100.
   PubMed Web of Science ®Google Scholar
• Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004;5:524–30. doi:10.1038/ni1058.
   PubMed Web of Science ®Google Scholar
• Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J, et al. MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2016;15:2155–65. doi:10.1158/1535-7163.MCT-15-0003.
   PubMed Web of Science ®Google Scholar
• Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAffee D, Birnbaum ME, Yang X, Su LF, Yu W, et al. Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding. Cell. 2018;174:672–687.e27. doi:10.1016/j.cell.2018.06.017.
   PubMed Web of Science ®Google Scholar
• Harris KE, Aldred SF, Davison LM, Ogana HAN, Boudreau A, Brüggemann M, Osborn M, Ma B, Buelow B, Clarke SC, et al. Sequence-based discovery demonstrates that fixed light chain human transgenic rats produce a diverse repertoire of antigen-specific antibodies. Front Immunol. 2018;9:889. doi:10.3389/fimmu.2018.00889.
   PubMed Web of Science ®Google Scholar
• Osborn MJ, Ma B, Avis S, Binnie A, Dilley J, Yang X, Lindquist K, Ménoret S, Iscache A-L, Ouisse L-H, et al. High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region. J Immunol Baltim Md. 2013 [1950];190:1481–90.
   PubMed Web of Science ®Google Scholar
• Ma B, Osborn MJ, Avis S, Ouisse L-H, Ménoret S, Anegon I, Buelow R, Brüggemann M. Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions. J Immunol Methods. 2013;400–401:78–86. doi:10.1016/j.jim.2013.10.007.
   PubMed Web of Science ®Google Scholar
• Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, Jenkins SS, Wood A, Cui X, Meng X, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science. 2009;325:433. doi:10.1126/science.1172447.
   PubMed Web of Science ®Google Scholar
• Kocks C, Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc Natl Acad Sci U S A. 1988;85:8206–10. doi:10.1073/pnas.85.21.8206.
   PubMed Web of Science ®Google Scholar
• Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541–70. doi:10.1146/annurev.immunol.23.021704.115830.
   PubMed Web of Science ®Google Scholar
• J-P B, Dubois ARSX, Faison WJ, Farinelle S, Charpentier E, Sinner R, Wienecke-Baldacchino A, Muller CP. Functionally convergent B cell receptor sequences in transgenic rats expressing a human B cell repertoire in response to tetanus toxoid and measles antigens. Front Immunol. 2017;8:1834. doi:10.3389/fimmu.2017.01834.
   PubMed Web of Science ®Google Scholar
• Blumberg RS, Ley S, Sancho J, Lonberg N, Lacy E, McDermott F, Schad V, Greenstein JL, Terhorst C. Structure of the T-cell antigen receptor: evidence for two CD3 epsilon subunits in the T-cell receptor-CD3 complex. Proc Natl Acad Sci U S A. 1990;87:7220–24. doi:10.1073/pnas.87.18.7220.
   PubMed Web of Science ®Google Scholar
• Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell. 2002;111:967–79. doi:10.1016/S0092-8674(02)01194-7.
   PubMed Web of Science ®Google Scholar
• Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med. 1991;173:1483–91. doi:10.1084/jem.173.6.1483.
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200:16–26. doi:10.1006/cimm.2000.1617.
   PubMed Web of Science ®Google Scholar
• Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci Publ Protein Soc. 1997;6:407–15. doi:10.1002/pro.5560060217.
   PubMed Web of Science ®Google Scholar
• Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol Baltim Md. 2000 [1950];164:1925–33.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–81. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–21. doi:10.1093/protein/9.7.617.
   PubMedGoogle Scholar
• Zou X, Osborn MJ, Bolland DJ, Smith JA, Corcos D, Hamon M, Oxley D, Hutchings A, Morgan G, Santos F, et al. Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. J Exp Med. 2007;204:3271–83. doi:10.1084/jem.20071155.
   PubMed Web of Science ®Google Scholar
• Clarke SC, Ma B, Trinklein ND, Schellenberger U, Osborn MJ, Ouisse L-H, Boudreau A, Davison LM, Harris KE, Ugamraj HS, et al. Multispecific antibody development platform based on human heavy chain antibodies. Front Immunol Internet]. 2019; 9. doi:10.3389/fimmu.2018.03037/full.
   PubMed Web of Science ®Google Scholar
• Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol Baltim Md. 2007 [1950];179:2815–23.
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai Y-T, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:2278. doi:10.1038/leu.2017.14.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410. doi:10.1016/j.ccell.2017.02.002.
   PubMed Web of Science ®Google Scholar
• Saber H, Del Valle P, Ricks TK, Leighton JK. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol RTP. 2017;90:144–52. doi:10.1016/j.yrtph.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? mAbs. 2011;3:61–66. doi:10.4161/mabs.3.1.13799.
   PubMed Web of Science ®Google Scholar
• Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nat Rev Immunol. 2013;13:257–69. doi:10.1038/nri3403.
   PubMed Web of Science ®Google Scholar
• Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18:485–97. doi:10.1038/s41577-018-0020-8.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin N, Risueno RM, Morreale A, Zaldivar I, Fernandez-Arenas E, Herranz F, Ortiz AR, Alarcon B. Cooperativity between T cell receptor complexes revealed by conformational mutants of CD3. Sci Signal. 2009;2:ra43–ra43. doi:10.1126/scisignal.2000402.
   PubMed Web of Science ®Google Scholar
• Matz M, Shagin D, Bogdanova E, Britanova O, Lukyanov S, Diatchenko L, Chenchik A. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res. 1999;27:1558–60. doi:10.1093/nar/27.6.1558.
   PubMed Web of Science ®Google Scholar
• Scherer EM, Smith RA, Gallego DF, Carter JJ, Wipf GC, Hoyos M, Stern M, Thurston T, Trinklein ND, Wald A, et al. A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine. 2016;10:55–64. doi:10.1016/j.ebiom.2016.06.042.
   PubMed Web of Science ®Google Scholar
• Son MS, Taylor RK. Preparing DNA libraries for multiplexed paired-end deep sequencing for Illumina GA sequencers. Curr Protoc Microbiol. 2011; Chapter 1: Unit1E.4.1-4.13.
   Google Scholar
• Néron S, Thibault L, Dussault N, Côté G, Ducas E, Pineault N, Roy A. Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells. Transfusion (Paris). 2007;47:1042–49. doi:10.1111/j.1537-2995.2007.01233.x.
   PubMed Web of Science ®Google Scholar